CorMedix Inc. generated $101.9 million in consolidated Revenue for the second quarter of 2026, reflecting a strong performance driven by increased sales of DefenCath. This growth positions the company favorably for investors as it raises its full-year adjusted EBITDA forecast to a range of $125 million to $140 million.

Key Highlights

  • DefenCath sales totaled $66.1 million, driven by Demand from major outpatient dialysis customers.
  • For Q2 2026, CorMedix recorded consolidated revenue that encompassed $66.1 million from DefenCath sales and $35.8 million from the acquired Melinta portfolio.
  • For the second quarter of 2026, adjusted EBITDA stood at $58.7 million, up from $22.4 million in the same quarter last year.

CorMedix Inc. (NASDAQ: CRMD), a biotechnology company focused on therapeutic solutions, achieved consolidated revenue of $101.9 million for the second quarter of 2026, exemplifying a significant year-over-year increase from $39.7 million in the same period in 2025. The company's strong financial performance underscores its operational capabilities and positive market position. Net Income for the quarter reached $26 million, yielding Earnings Per Share of $0.29, surpassing the consensus estimate of $0.24.

Amid a challenging market backdrop, CorMedix's growth is noteworthy and appeals to investors seeking strong performance metrics.

$101.9M in Consolidated Revenue

For Q2 2026, CorMedix recorded consolidated revenue that encompassed $66.1 million from DefenCath sales and $35.8 million from the acquired Melinta portfolio. This represents a remarkable year-over-year growth driven largely by DefenCath's ongoing demand. The inclusion of Melinta's revenue catalyzed this change, contributing to the quarterly figures following its Acquisition in August 2025.

This growth trajectory establishes CorMedix as a prominent player in its sector and signals a strong operational outlook for investors.

Adjusted EBITDA Raised

For the second quarter of 2026, adjusted EBITDA stood at $58.7 million, up from $22.4 million in the same quarter last year. This increase reflects not only revenue growth but also better management of operational costs, which, at $34.2 million, mark an increase driven by the integration of Melinta's expenses. Rising adjusted EBITDA might indicate operational efficiency and a positive future profit trajectory, enhancing investor sentiment.

Positive Market Signal

This comes as year-to-date performance remains down 35.5%. The company is currently dealing with a short interest of 21% of outstanding shares, which could influence market dynamics moving forward. Trading above its 20-day Moving Average of $7.64 highlights a potential recovery effort amidst the bearish sentiment observed this year.

With the first resistance level set at $8.63, achieving breakout momentum could invite renewed investor interest, especially as clinical developments continue to unfold.

What to Watch Next

CorMedix's conference call on August 13, 2026, will provide investors with insights into the company's strategies moving forward, including updates on regulatory submissions and clinical developments. Investors should pay close attention to upcoming announcements, particularly regarding FDA submissions for the REZZAYO indication anticipated later this quarter. Such developments are vital for assessing CorMedix's ability to Capitalize on its expanding market opportunities.

Peers Moving on This News